The interim analysis conducted by the Data Safety Monitoring Board (DSMB) evaluated stroke patients’ outcome 90 days following an acute ischemic stroke, comparing treatment with Viprinex to treatment with placebo.
The DSMB determined that there was no clinically meaningful difference in outcome between the two treatment groups as measured on the modified Rankin scale of disability, the primary endpoint of the study. Neurobiological Technologies will obtain and analyze the data before evaluating the potential for any future development of Viprinex.
Paul Freiman, president and CEO of Neurobiological Technologies, said: “We are deeply disappointed that Viprinex did not improve overall patient outcomes in our clinical study. This news is a significant set-back for our clinical program.
“Once we obtain the data and we have analyzed the results from this study, which we expect to occur in early 2009, we will determine whether we will pursue any further development of Viprinex.”